Pharmacotherapy for BPH (Benign Prostatic Hyperplasia)
Buy non prescription drugs: Asacol, Diamox
Mechanisms of Obstruction and Rationale for Pharmacotherapy
Current pharmacotherapy for Benign Prostatic Hyperplasia (BPH) is based on agents that relax the smooth muscles of prostatic urethra and stroma and those that deprive acinar cells of androgen.
Various agents have been tried in the treatment of BPH (Table). They may be broadly grouped into those affecting the dynamic component of urethral obstruction, namely the smooth muscle and prostatic stroma, and those affecting the glandular elements by androgen deprivation. The mechanism of action of many agents claimed to be useful in Benign Prostatic Hyperplasia is not clearly understood.
| TABLE — Drugs That Have Been Tried in the Medical Management of Benign Prostatic Hyperplasia (Some agents act by more than one mechanism) |
||
| Drug Class | Drug (Code Designation) | Trade Name |
| α1-Adrenergic antagonists | ||
| Prazosin HCl | Minipress | |
| Terazosin HCl | Hytrin | |
| Doxazosin mesylate | Cardura | |
| Phentolamine mesylate | ||
| YM-617 | ||
| Nicergoline | Sermion | |
| Indoramin | Baratol | |
| Ketanserin | ||
| Yohimbine HCI | ||
| Antiandrogens | ||
| Selective | ||
| 5α-Reductase inhibitors | Finasteride | Proscar |
| Epristeride | ||
| Agents blocking androgen uptake and causing receptor blockade | Flutamide | Eulexin |
| Cyproterone acetate | ||
| Nilutamide | Nilandron | |
| Oxendolone | Prostetin | |
| Gestonorone caproate | Depostat | |
| Casodex (10176,334) | ||
| Nonselective | ||
| Gn-RH analogues | Nafarelin acetate | Synarel |
| Leuprolide acetate | Lupron | |
| Goserelin acetate | Zoladex | |
| Estrogens | Diethylstilbestrol | |
| Chlorotrianisene | TACE | |
| Progestational agents | Megestrol acetate | Megace Primostat |
| Hydroxyprogesterone acetate | ||
| Hydroxyprogesterone caproate | ||
| Medrogestone | ||
| Aromatase inhibitors | Testolactone | Teslac |
| Atamestane | ||
| Steroidogenesis inhibitors | Aminoglutethimide | |
| Ketoconazole | Nizoral | |
| Prolactin inhibitor | Bromocriptine mesylate | |
| Miscellaneous agents | Candicidin | |
| Sitoglustde (WA184) | ||
| Probucol | ||
| Cimetidine | Tagamet | |
| Physosterols | ||
| Extract of the plant Serenoa repens | Permixon | |
| Spironolactone | Aldactone | |
| Tamoxifen citrate | ||
| Bazoton | ||
| Fluorouracil | ||
| Gn-RH – gonadotropin-releasing hormone, HCl – hydrochloride | ||
Caine has suggested that obstruction due to Benign Prostatic Hyperplasia occurs because of two factors: a dynamic component is thought to occur as a result of the contraction of smooth muscles of the prostate and prostatic urethra and is mediated mostly by adrenergic receptors; and a mechanical component of obstruction is related to the presence of a mass of hyperplastic acinar or stromal tissue that compresses and narrows the urethral lumen. There is some evidence that the presence and density of stromal content in BPH may relate to the severity of obstruction.
Current understanding of the biologic mechanisms of obstruction is limited and does not extend to two common clinical facts. The first is that the size of the prostate does not always correlate with the severity of symptoms or objective signs of obstruction. The second is the discrepancy between the histologic changes of BPH and the presence and severity of symptoms. From a physiologic standpoint, five conditions in patients with symptoms of “BPH” may exist singly or in combination. These are prostatic urethral obstruction, impaired detrusor contractility, detrusor instability, sensory urgency, and primary vesical neck obstruction. All these conditions likely result from varying combinations of prostatic enlargement and subtle neurologic dysfunction, all due to age-related central nervous system degeneration. Alternatively, a hyperplastic prostate during growth may disrupt normal sphincteric function. Thus, it is not surprising that prostatectomy fails to relieve symptoms of prostatism in about 20% of patients because the symptoms may be caused by poorly understood deficits in neurosensory pathways regulating micturition and sphincteric function.
Transurethral prostatectomy is the most common surgical procedure currently performed for the treatment of Benign Prostatic Hyperplasia. Outcome analyses have questioned the results of transurethral resection of the prostate (TURP). Patients undergoing TURP have been reported to be at greater risk from cardiovascular death than patients undergoing open prostatectomy. Recently these findings were disputed, and it was reported that transurethral resection for BPH does not increase long-term mortality and that comorbid illnesses and older age probably account for the apparent increase in long-term mortality after TURP. The morbidity of the procedure remains unchanged, however. In a review in 1962, the morbidity after transurethral resection of the prostate was reported to be 18% and the mortality 2.5%. More recently, the American Urological Association (AUA) cooperative study of 3,885 patients after the procedure revealed an overall complication rate of 18% and 0.2% mortality. Thus, the search for alternative therapies has been prompted by patients’ preferences for less invasive forms of treatment without prohibitive side effects. Apart from pharmacotherapy, other methods undergoing trials for the treatment of Benign Prostatic Hyperplasia include laser ablation, microwave hyperthermia, and prostatic stents. Ultimately, the role of surgical treatment and newer modalities must be based on relative effectiveness, cost, morbidity, effect on quality of life, expectations, and treatment preferences of patients.
Buy non prescription drugs: Asacol, Diamox
This post has been viewed 310 times.
Related posts:
- Management of Benign Prostatic Hyperplasia (BPH): Pharmacotherapy Buy non prescription drugs: Asacol, Diamox Pharmacologic agents designed to relax prostatic smooth muscle (alpha-adrenergic blockers) and reduce prostatic size (androgen suppression) have been reported to be safe and effective in treating benign prostatic hyperplasia (BPH). The selective alpha-1 blockers doxazosin and terazosin,...
- The management of benign prostatic hyperplasia: Pharmacotherapy Buy non prescription drugs: Asacol, Diamox Recent developments in drug therapy have reduced the number of surgical procedures needed, although in men with severe symptoms, medications may delay but not prevent the need for surgery. Pharmacotherapy has been shown to result in clinically...
- Management of benign prostatic hyperplasia (BPH) Buy non prescription drugs: Asacol, Diamox The National Prescribing Centre (NPC) [UK] Summary Symptoms of benign prostatic hyperplasia (BPH) are common in older men. They result from hyperplasia of glandular tissue and increased smooth muscle tone. Many men accept these symptoms as a...
- Treatments for Benign Prostatic Hyperplasia. Part 4 Buy non prescription drugs: Asacol, Diamox Transurethral prostatic resection Efficacy. Lepor and Rigaud critically examined the efficacy of transurethral prostatectomy in men with moderate symptoms of prostatism. They assessed subjective outcome using a popular standardized symptom score formulated by Boyarsky and colleagues, as...
- Treatments for Benign Prostatic Hyperplasia. Part 1 Buy non prescription drugs: Asacol, Diamox Benign Prostatic Hyperplasia (BPH) is the most common neoplasm affecting humans. More than 400 000 prostatectomies are performed annually in the United States, second only to cataract extractions in charges to Medicare. In an era of limited...
Posted in: Pharmacotherapy